IPO - Profile


Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$12.00 3,750,000 Positive High 23.2%

Offering Team

  • Legal counsel
  • DLA Piper LLP
  • Auditors

Deal Highlights

We are a commercial-stage precision diagnostics company committed to providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care. Our novel prostate cancer genomic testing solutions, SelectMDx and ConfirmMDx, provide physicians with a clear clinical pathway to accurately identify clinically significant prostate cancer while minimizing the use of invasive procedures that are prone to complications. Our unique approach combines advanced clinical modeling with genomic data to provide each patient with a personalized cancer risk profile, which provides more accurate and actionable information than standard risk factors (e.g., PSA, DRE, age) used by clinicians. Our lead products address men at risk for developing prostate cancer. In addition, we are actively developing testing solutions to help with the management of men diagnosed with prostate cancer, with the goal to provide our clients with a menu of tools spanning the continuum of prostate cancer diagnosis and care. Our team’s collective decades of experience in precision diagnostics and our portfolio of novel biomarkers for diagnostic, prognostic and predictive molecular assays supports our active pipeline of new testing solutions for prostate and other urologic diseases.

Deal Tracker

IPO Dates

Filing 28 Oct, 2021

Offer 04 Nov, 2021

Look Ahead

Lock Up Expiry May 04, 2022

IPO Terms

Offer Price $12.00
Offer Size 3M

Market Sentiments

Stock Price